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Table 3. Mean difference in HRQL across all randomised patients between 






17 µ Diff lCI uCI 
Global 58 64.80 68.25 3.45 -1.46 8.36 
Functional       
Physical 59 79.89 78.45 -1.44 -5.94 3.06 
Role 59 70.90 69.77 -1.13 -8.43 6.17 
Emotional 59 75.71 77.68 1.98 -2.77 6.72 
Cognitive 59 82.20 78.81 -3.39 -7.64 0.86 
Social 58 65.52 70.98 5.46 -1.85 12.77 
Symptoms       
Fatigue 59 37.29 37.85 0.56 -6.12 7.25 
Nausea 59 14.69 12.71 -1.98 -7.69 3.73 
Pain 59 31.36 20.34 -11.02 -18.08 -3.96 
Dyspnoea 58 13.22 18.39 5.17 -1.14 11.49 
Insomnia 59 34.46 27.12 -7.34 -14.57 -0.12 
Appetite 59 36.72 23.16 -13.56 -23.90 -3.22 
Constipation 58 18.39 12.64 -5.75 -11.47 -0.03 
Diarrhoea 58 20.11 25.29 5.17 -1.75 12.10 
Financial 57 21.05 17.54 -3.51 -11.47 4.45 
Panc Pain 58 36.83 22.51 -14.32 -21.02 -7.62 
Bloating 57 32.75 22.81 -9.94 -17.03 -2.86 
Gastro 58 35.92 28.74 -7.18 -16.14 1.78 
Taste 58 27.01 32.18 5.17 -4.37 14.72 
Indigestion 56 25.60 22.02 -3.57 -12.03 4.88 
Flatulence 58 48.85 48.28 -0.57 -11.65 10.50 
Weight 58 40.80 30.46 -10.34 -20.62 -0.06 
Weak limbs 58 27.01 33.33 6.32 0.08 12.56 
Dry mouth 58 32.18 31.03 -1.15 -10.43 8.13 
Jaundice 55 16.97 11.82 -5.15 -10.96 0.66 
Bowel 58 34.48 34.77 0.29 -7.78 8.35 
Image 57 26.02 27.49 1.46 -6.78 9.70 
Side effects 49 15.65 30.61 14.97 5.38 24.55 
Future 55 58.18 47.88 -10.30 -18.78 -1.83 
Planning 57 40.35 33.92 -6.43 -17.58 4.71 
Healthcare 57 85.96 89.18 3.22 -4.28 10.71 
Sexual 43 50.00 51.94 1.94 -10.23 14.11 
Abbreviations: µ=mean; lCI=lower 95% confidence interval; uCI=upper 95% confidence interval;  Diff= 
difference between means 
NB High scores in function scales (and SatHC) represent better HRQLand higher scores in symptom scales 
represent worse HRQL. Negative differences in function scales represent HRQLworsening whereas negative 
differences in symptom scores represents HRQL improvement. Clinically significant differences are highlighted in 





Table 4. Mean difference in HRQL across all randomised patients between week 17 and later timepoints  
 
 
   Week 23-17 Week 26-17  Week 39-17 
Scale n Wk 17 µ Wk 23 µ Diff lCI uCI n Wk 17 µ Wk 26 µ Diff lCI uCI n Wk 17 µ Wk 39 µ Diff lCI uCI 
Functional                                     
GQOL 46 68.84 62.32 -6.52 -12.49 -0.55 46 67.39 61.96 -5.43 -12.76 1.89 37 66.44 61.71 -4.73 -11.62 2.16 
Physical 47 77.84 72.06 -5.78 -9.65 -1.91 47 78.55 76.35 -2.20 -6.95 2.55 37 76.76 74.59 -2.16 -6.88 2.55 
Role 47 70.92 63.48 -7.45 -15.66 0.77 47 69.15 64.89 -4.26 -13.85 5.34 37 66.22 63.51 -2.70 -12.01 6.61 
Emotional 47 78.55 73.17 -5.38 -10.08 -0.68 47 76.95 68.09 -8.87 -15.51 -2.22 38 77.85 68.64 -9.21 -16.49 -1.93 
Cognitive 47 80.50 77.66 -2.84 -6.96 1.29 47 79.08 75.89 -3.19 -8.65 2.27 38 76.75 74.12 -2.63 -10.22 4.96 
Social 46 69.20 65.58 -3.62 -9.33 2.08 46 66.67 64.86 -1.81 -11.72 8.10 37 63.06 63.06 0.00 -8.49 8.49 
Symptoms                                     
Fatigue 47 35.22 46.93 11.70 5.34 18.07 47 38.06 40.90 2.84 -3.53 9.20 38 40.35 37.72 -2.63 -10.39 5.12 
Nausea 47 12.06 20.21 8.16 1.17 15.14 47 13.12 15.25 2.13 -6.07 10.33 38 11.84 10.53 -1.32 -7.07 4.43 
Pain 47 20.92 24.82 3.90 -3.54 11.34 47 21.99 26.24 4.26 -4.73 13.24 38 20.61 31.58 10.96 0.52 21.41 
Dyspnoea 46 19.57 23.91 4.35 -2.12 10.82 47 20.57 24.82 4.26 -4.06 12.57 36 22.22 16.67 -5.56 -13.87 2.75 
Insomnia 47 26.24 26.24 0.00 -7.36 7.36 46 28.26 31.16 2.90 -7.50 13.30 37 27.93 28.83 0.90 -8.36 10.16 
Appetite 46 19.57 39.13 19.57 7.65 31.48 47 23.40 30.50 7.09 -2.02 16.20 37 23.42 26.13 2.70 -7.90 13.30 
Constipation 46 14.49 16.67 2.17 -4.56 8.90 46 15.94 18.12 2.17 -3.50 7.85 38 15.79 14.91 -0.88 -7.37 5.61 
Diarrhoea 47 19.86 21.99 2.13 -5.34 9.60 46 23.19 23.19 0.00 -8.85 8.85 38 21.93 21.05 -0.88 -7.37 5.61 
Financial 46 20.29 22.46 2.17 -5.18 9.52 46 18.12 23.91 5.80 -1.22 12.81 37 20.72 14.41 -6.31 -14.93 2.32 
Panc Pain 45 21.85 27.59 5.74 0.72 10.77 46 24.46 27.54 3.08 -3.03 9.19 37 22.45 30.18 7.73 -0.55 16.02 
Bloating 45 19.26 24.44 5.19 -2.50 12.87 46 25.36 25.36 0.00 -7.81 7.81 37 20.72 31.53 10.81 0.99 20.63 
Gastro 45 25.56 37.78 12.22 2.83 21.61 46 30.80 32.61 1.81 -7.59 11.22 37 27.03 23.87 -3.15 -13.62 7.31 
Taste 45 31.11 35.56 4.44 -5.48 14.37 46 36.96 36.23 -0.72 -9.70 8.25 37 29.73 24.32 -5.41 -15.04 4.22 
Indigestion 44 20.45 21.97 1.52 -8.25 11.28 43 25.58 17.83 -7.75 -16.94 1.43 37 22.52 30.63 8.11 -2.50 18.72 
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Flatulence 45 43.70 48.89 5.19 -5.69 16.06 46 47.10 42.75 -4.35 -13.59 4.89 35 53.33 49.52 -3.81 -14.84 7.22 
Weight 45 30.37 38.52 8.15 -0.16 16.46 45 29.63 34.81 5.19 -6.88 17.25 37 31.53 31.53 0.00 -9.07 9.07 
Weak limbs 45 30.37 31.85 1.48 -5.90 8.86 46 31.16 35.51 4.35 -4.89 13.59 36 33.33 30.56 -2.78 -11.46 5.91 
Dry mouth 44 28.79 27.27 -1.52 -9.38 6.35 44 29.55 26.52 -3.03 -13.70 7.64 37 28.83 22.52 -6.31 -14.93 2.32 
Jaundice 43 10.08 8.53 -1.55 -6.41 3.30 44 10.23 9.09 -1.14 -6.64 4.37 33 13.64 10.61 -3.03 -11.32 5.26 
Bowel 45 31.11 34.07 2.96 -5.12 11.04 46 35.51 40.22 4.71 -3.21 12.63 37 37.39 45.50 8.11 -0.84 17.05 
Image 45 25.93 24.81 -1.11 -7.37 5.15 45 27.78 34.07 6.30 -2.53 15.12 37 28.83 34.68 5.86 -2.55 14.26 
Side effects 45 28.15 37.78 9.63 3.36 15.90 45 34.07 33.33 -0.74 -9.41 7.93 37 35.14 30.63 -4.50 -12.86 3.85 
Future 45 48.89 57.78 8.89 -1.22 18.99 46 51.45 57.97 6.52 -3.18 16.22 37 50.45 56.76 6.31 -4.76 17.37 
Planning 44 34.09 38.64 4.55 -4.08 13.18 46 37.68 38.41 0.72 -9.81 11.26 37 38.74 42.34 3.60 -7.13 14.34 
Healthcare 45 89.63 91.48 1.85 -6.77 10.47 46 92.03 92.03 0.00 -7.60 7.60 37 92.34 84.23 -8.11 -18.96 2.74 
Sexual 36 53.70 60.65 6.94 -4.20 18.09 38 53.95 53.95 0.00 -11.32 11.32 30 49.44 58.33 8.89 -3.95 21.73 
Abbreviations: µ=mean; lCI=lower 95% confidence interval; uCI=upper 95% confidence interval; Diff= difference between means; scale abbreviations as shown in Table 1. 
NB High scores in functioning scales (and SatHC) represent better HRQL and higher scores in symptom scales represent worse HRQL. Negative differences in functioning scales (and SatHC) 
represent HRQLworsening whereas negative differences in symptom scores represent HRQLimprovement. Clinically significant differences are highlighted in bold. 
 




Table 5. Difference in HRQL between week 17 and later timepoints by trial arm 
 
  
Week 23-Week 17 
Week 26-Week 17 Week 39-Week 17 
  
Capecitabine Gemcitabine 










week 17 n 
Median 
difference in 
score (range) z p n 
Median 
difference in 
score (range)  n 
Median 
difference in 
score (range) z p n 
Median 
difference in 
score (range) n 
Median 
difference in 
score (range) z p 
Func.      
 




(-33.3,41.7) 66.7 23 
-16.7  








(-58.3,33.3) 1.21 0.227 
Physical 86.7 23 
0.0  
(-40.0,26.7) 73.3 24 
-10.0  








(-40.0,13.3) 1.28 0.199 
Role 83.3 23 
0.0  
(-50.0,66.7) 66.7 24 
-16.7  








(-66.7,33.3) 1.22 0.223 
Emotional 83.3 23 
0.0  
(-58.3,16.7) 75.0 24 
0.0  








(-75.0,50.0) 0.53 0.598 
Cognitive 83.3 23 
0.0  
(-16.7,16.7) 83.3 24 
0.0  








(-50.0,33.3) 2.54 0.011 
Social 83.3 23 
0.0  
(-66.7,50.0) 66.7 23 
0.0 








(-66.7,33.3) -0.02 0.987 
Symp.      
 
                                
Fatigue 33.3 23 
11.1  
(-33.3,44.4) 33.3 24 
16.7  








(-22.2,44.4) -1.47 0.142 
Nausea 0.0 23 
0.0  
(-33.3,50.0) 16.7 24 
8.3  








(-33.3,0.0) 1.83 0.067 
Pain 16.7 23 
0.0  
(-33.3,33.3) 16.7 24 
0.0  








(-50.0,66.7) -0.61 0.545 
Dyspnoea 0.0 22 
0.0  
(-66.7,33.3) 33.3 24 
0.0  








(-33.3,66.7) -1.38 0.167 
Insomnia 33.3 23 
0.0  
(-66.7,33.3) 0.0 24 
0.0  








 (-33.3,66.7) -0.96 0.335 
Appetite 0.0 23 
0.0  
(-66.7,100.0) 33.3 23 
33.3  




(-33.3,66.7) -0.80 0.421 22 
0.0 
 (-33.3,100.0) 15 
0.0  
(-66.7,66.7) 0.12 0.904 
Constipation 0.0 22 
0.0  
(-33.3,66.7) 0.0 24 
0.0  




(-33.3,33.3) -0.65 0.516 23 
0.0 
 (-66.7,33.3) 15 
0.0  
(-33.3,33.3) -0.66 0.511 
Diarrhoea 0.0 23 
0.0  
(-33.3,33.3) 33.3 24 
0.0  








 (-33.3,33.3) -0.21 0.831 
Financial 0.0 23 
0.0  
(-33.3,33.3) 0.0 23 
0.0  








(-66.7,33.3) 0.51 0.613 
Panc Pain 8.3 23 
0.0  
(-33.3,33.3) 25.0 22 
8.3  








 (-33.3,75.0) 0.19 0.851 
Bloating 0.0 23 
0.0  
(-33.3,33.3) 33.3 22 
0.0  








(-33.3,33.3) 0.42 0.674 
Gastro 16.7 23 
0.0  
(-16.7,100.0) 33.3 22 
8.3 (-




(-50.0,100.0) 0.35 0.726 22 
0.0 
 (-66.7,66.7) 15 
-16.7  
(-50.0,50.0) 1.66 0.097 
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Taste 33.3 23 
0.0  
(-100.0,66.7) 33.3 22 
0.0 (-








(-66.7,33.3) -0.34 0.732 
Indigestion 0.0 22 
0.0  
(-33.3,100.0) 33.3 22 
0.0  




(-66.7,33.3) 1.17 0.244 22 
0.0  
(-66.7,100.0) 15 0.0 (0.0,33.3) -0.45 0.651 
Flatulence 33.3 23 
0.0  
(-33.3,100.0) 33.3 22 
0.0  








(-33.3,33.3) 0.19 0.852 
Weight 33.3 23 
0.0  
(-33.3,66.7) 33.3 22 
0.0  








(-66.7,66.7) 0.34 0.738 
Weak limbs 33.3 23 
0.0  
(-66.7,33.3) 33.3 22 
0.0  








 (-33.3,66.7) -1.62 0.104 
Dry mouth 33.3 22 
0.0 
 (-66.7,33.3) 33.3 22 
0.0  








(-33.3,33.3) -3.44 0.001 
Jaundice 0.0 22 
0.0  
(-33.3,50.0) 0.0 21 
0.0  








 (-66.7,33.3) -0.12 0.907 
Bowel 33.3 23 
0.0  
(-33.3,66.7) 50.0 22 
0.0  








 (-33.3,50.0) 0.00 1.000 
Image 33.3 23 
0.0  
(-33.3,50.0) 0.0 22 
0.0  








 (-16.7,66.7) -2.29 0.022 
Side effects 33.3 23 
0.0  
(-33.3,33.3) 33.3 22 
0.0 (-








(-33.3,33.3) -0.02 0.987 
Future 66.7 23 
0.0  
(-33.3,66.7) 33.3 22 
0.0  








 (-66.7,66.7) -0.52 0.600 
Planning 33.3 23 
0.0  
(-33.3,66.7) 33.3 21 
0.0  








(-33.3,66.7) -0.80 0.426 
Healthcare 100.0 23 
0.0  
(-100,100) 100.0 22 
0.0  








(-50.0,50.0) -1.91 0.056 
Sexual 41.7 20 
0.0 
(-66.7,66.7) 66.7 16 
0.0  
(-100.0,83.3) -0.07 0.941 20 0.0 (0.0,66.7) 18 
0.0  




(-100.0,83.3) -0.55 0.583 
 
 
NB: Negative differences in functioning scales (and SatHC) represent HRQL worsening whereas negative differences in symptom scores represents HRQL improvement. Abbreviations as 






Table 6. Mean week 23 QLQ-PAN26 scale scores by those with and without any CTCAE grade 3 or 4 adverse events during CRT 
 
 PAN 26 scale No grade 3 or 4 adverse events during CRT Any Grade 3 or 4 adverse events during CRT 
  n Mean Lower 95% CI Upper 95% CI n Mean Lower 95% CI Upper 95% CI 
Pancreatic pain* 38 23.90 16.93 30.88 10 36.67 18.20 55.14 
Bloating* 38 20.18 11.52 28.83 10 36.67 15.79 57.55 
Gastrointestinal* 38 32.89 21.40 44.39 10 58.33 35.68 80.99 
Taste loss 38 34.21 24.19 44.24 10 40.00 10.69 69.31 
Indigestion 38 21.05 11.38 30.73 10 23.33 0.71 45.95 
Flatulence 38 45.61 34.98 56.25 10 50.00 26.83 73.17 
Weight* 38 31.58 20.20 42.96 10 63.33 32.65 94.01 
Weak limbs* 38 26.32 17.43 35.20 10 53.33 30.30 76.37 
Dry mouth 37 28.83 18.63 39.03 10 23.33 3.70 42.96 
Jaundice 38 7.89 2.84 12.95 10 8.33 2.05 14.62 
Altered bowel habit* 38 28.51 18.41 38.61 10 58.33 33.67 82.99 
Poor body image 38 25.44 14.80 36.07 10 25.00 3.05 46.95 
Side effects of treatment 38 35.96 27.37 44.56 10 36.67 12.95 60.38 
Future health concern* 38 51.75 39.89 63.62 10 73.33 48.71 97.96 
Forward planning limited* 37 33.33 21.91 44.75 10 56.67 37.04 76.30 
Satisfaction with healthcare 38 92.11 85.52 98.69 10 91.67 81.53 101.80 
Sexual dissatisfaction 31 59.14 43.45 74.83 7 66.67 32.20 101.13 
 *indicates a difference in means of more than 10 points 
  
